通过使用经过验证的LC-ESI-MS/MS生物分析方法和药学动力学评估量化比较性药物动力学参数来评估含有西利尼迪平的自微乳化药物输送系统 (SMEDDS)
Kumar Anand1, Pallab Mandal1, Samit Karmakar2
1Bioequivalence Study Centre, Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700032, West Bengal, India.
Annales pharmaceutiques francaises
|August 1, 2024
概括
这项研究开发了一种新的自微乳化药物递送系统 (SMEDDS),显著提高其药理动力学特征和生物可用性,与传统药片相比,在老鼠中显著提高. 优化的配方提供了改善的高血压治疗潜力.
科学领域:
- 制药科学 制药科学
- 药物输送系统 药物输送系统
- 药理动力学和药理动力学
背景情况:
- 许多有前途的药物由于溶解性和透性差,导致临床开发失败,需要先进的药物输送系统.
- 传统的剂量形式往往无法达到最佳的药理动力学和药理动力学特征的药物,如尼迪平.
- 尼迪平是一种1,4-二二胺通道阻塞剂,用于治疗高血压,但面临生物可用性挑战.
研究的目的:
- 开发和验证一种精确的LC-MS/MS方法来量化西利尼迪平的药理学参数.
- 在老鼠中评估一款载有西利尼迪平的自我微乳化药物输送系统 (SMEDDS) 的药理动力学.
- 将新型SMEDDS配方的性能与市场上销售的西尼迪平片进行比较,并探索剂量降低策略.
主要方法:
- 开发一种液体染色学-并联质谱法 (LC-MS/MS) 方法,用于在老鼠血中定量西尼迪平.
- 准备和优化装载着西尼迪平的自我微乳化药物输送系统 (SMEDDS).
- 在Wistar大鼠中的体内药理动力学和药理动力学评估,将SMEDDS与市场上销售的药片进行比较.
主要成果:
- 该LC-MS/MS方法显示高灵敏度和精确度,用于量化西尼迪平.
- 与市场上销售的片剂相比,口服优化的SMEDDS导致显著更高的顶峰血度 (Cmax) 和更快的Tmax.
- 这种SMEDDS配方在0.866±0.11小时时达到Cmax21.02±3.17 ng/mL,而在0.93±0.11小时时达到10.16±0.89 ng/mL的Cmax.
结论:
- 优化的西利尼迪平负载SMEDDS在Wistar大鼠中显示出优异的药理动力学参数.
- 新型SMEDDS配方与市场上销售的西尼迪平平片相比,其相对生物利用率大约提高了2.4倍.
- 这些发现与改进的非侵入性血压测量相关,这表明对高血压管理的治疗疗效有所提高.
相关概念视频
01:26Therapeutic Drug Monitoring: Drug Analysis Methods
342
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
342
01:30Modified-Release Drug Delivery Systems: Bioavailability
170
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
170
01:23Modified-Release Drug Delivery Systems: Classification
315
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
315
01:24Modified-Release Drug Delivery Systems: Site-Targeted
164
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
164
01:18Transdermal Drug Delivery Systems
233
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
233
01:21Intrauterine Drug Delivery Systems
168
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
168